What is Cagent Vascular?
Cagent Vascular Inc. is a specialized medical technology firm focused on the advancement of angioplasty procedures through its proprietary Serration Technology. The company's core innovation, the Serranator, is engineered to optimize lumen gain while minimizing the risk of complications during complex vascular interventions. By addressing critical unmet needs in cardiovascular care, Cagent Vascular has established itself as a pivotal player in the medical device industry, providing healthcare professionals with sophisticated tools designed to improve patient outcomes and enhance the quality of life for those suffering from cardiovascular disease.
How much funding has Cagent Vascular raised?
Cagent Vascular has raised a total of $107M across 6 funding rounds:
Series B
$11.9M
Debt
$150K
Private Equity
$9M
Series C
$30M
Private Equity
$15M
Series D
$41M
Series B (2018): $11.9M with participation from Ben Franklin Technology Partners, Balestier Investments, and Synergy Ventures
Debt (2020): $150K led by PPP
Private Equity (2021): $9M supported by Sectoral Asset Management
Series C (2024): $30M featuring Sectoral Asset Management and Blue Ridge Medical Center
Private Equity (2025): $15M backed by Trinity Capital
Series D (2026): $41M with participation from Astoria Investors and U.S. Venture Partners
Key Investors in Cagent Vascular
U.S. Venture Partners
A prominent Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, and healthcare sectors.
Sectoral Asset Management
An investment advisor specializing in managing global equities within the healthcare sector, with a strong track record in biotech and private equity strategies.
Astoria Investors
A California-based firm operating within the venture capital and private equity industry, focused on supporting high-growth enterprises.
What's next for Cagent Vascular?
With the successful closure of this latest funding round, Cagent Vascular is poised to transition into a new phase of commercial scaling and product iteration. The strategic deployment of these funds will likely focus on expanding the clinical evidence base for the Serranator, facilitating broader adoption among healthcare providers, and potentially exploring new indications for its proprietary technology. As the company matures, the focus will shift toward solidifying its market position as a leader in vascular intervention, ensuring that its innovative solutions remain at the forefront of clinical practice and patient care standards.
See full Cagent Vascular company page
